The Daily Biotech Pulse: Astrazeneca goes shopping, Tyme Technologies & Syros Pharma merger
The Daily Biotech Pulse: Astrazeneca goes shopping, Tyme Technologies & Syros Pharma merger
每日生物技術脈動：阿斯利康去購物，泰姆科技與 Syros 製藥合併
Here's a roundup of top developments in the biotech space over the last 24 hours:
以下是過去24小時生物技術領域的熱門發展綜述：
Stocks In Focus
關注的股票
AstraZeneca Strengthens Its Hematological Cancer Pipeline With TeneoTwo Acquisition
阿斯利康通過收購TeneoTwo加強其血液癌症管道
AstraZeneca(AZN.US) has agreed to acquire TeneoTwo, Inc, including its Phase 1 clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma.
阿斯利康(AZN.US)該公司已同意收購。TeneoTwo，Inc.，包括其臨床1期CD19/CD3 T細胞激活劑TNB-486，目前正在對復發和難治性B細胞非霍奇金淋巴瘤進行評估。
Deal consideration includes an upfront payment of $100 million. AstraZeneca will make additional contingent R&D-related milestone payments of up to $805 million and additional contingent commercial-related milestone payments of up to $360 million to TeneoTwo's equity holders.
交易對價包括1億美元的預付款。阿斯利康將向TeneoTwo的股東支付高達8.05億美元的額外或有研發相關里程碑付款，以及高達3.6億美元的額外或有商業相關里程碑付款。
TYME Technologies Shares Surge...
泰姆科技...
登入免費觀看全文
登入/註冊